Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
1.06
Nov 17 • 12:18 PM ET Dollar change-0.04 Percentage change(-3.64%)
Index
-
Market Cap
14.17M
Enterprise Value
-7.98M
Income
-26.66M
Sales
0.00M
Book/sh
1.65
Cash/sh
1.67
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
12
IPO
Jan 31, 2014
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
0.64
P/C
0.64
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
1.87
Current Ratio
2.86
Debt/Eq
0.01
LT Debt/Eq
0.00
Option/Short
Yes / Yes
EPS (ttm)
-2.67
EPS next Y
-1.65
EPS next Q
-0.46
EPS this Y
32.21%
EPS next Y
25.44%
EPS next 5Y
12.40%
EPS past 3/5Y
61.55% -
Sales past 3/5Y
- -
EPS Y/Y TTM
67.96%
Sales Y/Y TTM
-100.00%
EPS Q/Q
17.88%
Sales Q/Q
-
Insider Own
24.71%
Insider Trans
0.00%
Inst Own
23.10%
Inst Trans
-13.42%
ROA
-85.24%
ROE
-123.08%
ROIC
-172.49%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
5.15%
SMA50
-11.58%
SMA200
-58.62%
Trades
Shs Outstand
13.34M
Shs Float
10.04M
52W High
5.69 -81.37%
52W Low
0.77 37.15%
Volatility
15.55% 14.87%
ATR (14)
0.15
RSI (14)
47.80
Beta
0.22
Rel Volume
0.35
Avg Volume
239.40K
Volume
38,705
Perf Week
-24.82%
Perf Month
9.28%
Perf Quarter
-43.62%
Perf Half Y
-71.43%
Perf YTD
-75.35%
Perf Year
-73.70%
Perf 3Y
-97.32%
Perf 5Y
-99.80%
Perf 10Y
-99.75%
Prev Close
1.10
Price
1.06
Change %
-3.64%
Consensus
Buy
Avg. Price Target
$8.88
Implied Upside
+737.7%
Analysts12incl. previous ratings
Rating Distribution6 Buy · 4 Hold · 2 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 20, 2026Initiated
CChardan Capital Markets
Buy$8+654.7%
Jul 08, 2026Upgrade
RJF logoRRaymond James
Mkt Perform → Outperform$10+843.4%
Jul 08, 2026Upgrade
PPiper Sandler
Neutral → Overweight$13+1,126.4%
Jun 08, 2026Initiated
HH.C. Wainwright
Buy$9+749.1%
Apr 20, 2026Downgrade
BCS logoBBarclays
Equal Weight → Underweight$3+183.0%
Oct 14, 2025Downgrade
RJF logoRRaymond James
Outperform → Mkt Perform
Oct 14, 2025Downgrade
BCS logoBBarclays
Overweight → Equal Weight$5+371.7%
Oct 13, 2025Initiated
BCS logoBBarclays
Overweight$61+5,654.7%
Oct 13, 2025Downgrade
PPiper Sandler
Overweight → Neutral$78 → $4+277.4%
Oct 13, 2025Downgrade
CCantor Fitzgerald
Overweight → Neutral
Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. The company was founded in 2017 and is headquartered in Sugar Land, TX.
CEO & DirectorDr. Imran Alibhai Ph.D.
M.B.A.Mr. Dan Conn J.D.
Chief Medical OfficerDr. John Kauh M.D.
Co-Founder & Scientific Advisory Board MemberMr. David J. Tweardy M.D.
Co-Founder & Chairman of Scientific Advisory BoardDr. Ronald A. DePinho M.D.